Michele Gruber - Lipella Pharmaceuticals Director Operations
| LIPO Stock | 3.11 0.16 5.42% |
Director
Michele Gruber is Director Operations of Lipella Pharmaceuticals Common
| Address | 7800 Susquehanna St., Pittsburgh, PA, United States, 15208 |
| Phone | 412-901-0315 |
| Web | https://www.lipella.com |
Lipella Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.9377) % which means that it has lost $0.9377 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.7156) %, meaning that it created substantial loss on money invested by shareholders. Lipella Pharmaceuticals' management efficiency ratios could be used to measure how well Lipella Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of the 30th of November 2024, Return On Tangible Assets is likely to drop to -1.36. In addition to that, Return On Capital Employed is likely to grow to -1.41. At this time, Lipella Pharmaceuticals' Net Tangible Assets are very stable compared to the past year. As of the 30th of November 2024, Other Current Assets is likely to grow to about 174.6 K, while Total Assets are likely to drop about 2.8 M.Similar Executives
| Found 5 records | DIRECTOR Age | ||
| Susan Berland | Senti Biosciences | 69 | |
| John Zinckgraf | ImmuCell | N/A | |
| Adrian Haigh | Fennec Pharmaceuticals | 65 | |
| Elisabetta Castelli | Transgene SA | N/A | |
| Elizabeth Toothaker | ImmuCell | N/A | |
Management Performance
| Return On Equity | -1.72 | ||||
| Return On Asset | -0.94 |
Lipella Pharmaceuticals Leadership Team
Elected by the shareholders, the Lipella Pharmaceuticals' board of directors comprises two types of representatives: Lipella Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Lipella. The board's role is to monitor Lipella Pharmaceuticals' management team and ensure that shareholders' interests are well served. Lipella Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Lipella Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jonathan MBA, Chairman, CoFounder | ||
| Michele Gruber, Director Operations | ||
| Douglas CPA, Chief Officer | ||
| Michael MD, Chief CoFounder | ||
| Katie Johnston, Controller |
Lipella Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Lipella Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.72 | ||||
| Return On Asset | -0.94 | ||||
| Operating Margin | (6.98) % | ||||
| Current Valuation | 2.28 M | ||||
| Shares Outstanding | 1.21 M | ||||
| Shares Owned By Insiders | 29.37 % | ||||
| Shares Owned By Institutions | 6.51 % | ||||
| Number Of Shares Shorted | 25.1 K | ||||
| Price To Book | 2.44 X | ||||
| Price To Sales | 7.03 X |
Pair Trading with Lipella Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Lipella Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Lipella Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving against Lipella Stock
| 0.62 | BMY | Bristol Myers Squibb Sell-off Trend | PairCorr |
| 0.61 | VTRS | Viatris | PairCorr |
| 0.53 | ESPR | Esperion Therapeutics Buyout Trend | PairCorr |
| 0.49 | GILD | Gilead Sciences | PairCorr |
| 0.45 | WAT | Waters | PairCorr |
The ability to find closely correlated positions to Lipella Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Lipella Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Lipella Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Lipella Pharmaceuticals Common to buy it.
The correlation of Lipella Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Lipella Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Lipella Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Lipella Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lipella Pharmaceuticals Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lipella Pharmaceuticals. If investors know Lipella will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lipella Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.88) | Revenue Per Share 0.592 | Quarterly Revenue Growth 0.279 | Return On Assets (0.94) | Return On Equity (1.72) |
The market value of Lipella Pharmaceuticals is measured differently than its book value, which is the value of Lipella that is recorded on the company's balance sheet. Investors also form their own opinion of Lipella Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Lipella Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lipella Pharmaceuticals' market value can be influenced by many factors that don't directly affect Lipella Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lipella Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Lipella Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lipella Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.